NCT03016741View on ClinicalTrials.gov

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

January 4, 2023

Study Completion Date

August 31, 2029

Conditions
Castration-Resistant Prostatic CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate CancerHormone-Refractory Prostate Cancer
Interventions
BIOLOGICAL

GnRH agonist/antagonist

Given GnRH agonist/antagonist therapy

DRUG

Prednisone

Given by mouth

DRUG

Abiraterone Acetate

Given by mouth

DRUG

Enzalutamide

Given by mouth

Trial Locations (5)

37232

Vanderbilt-Ingram Cancer Center, Nashville

55455

University of Minnesota: Masonic Cancer Center, Minneapolis

60611

Northwestern University, Chicago

70112

Tulane Cancer Center, New Orleans

91010

City of Hope Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Northwestern University

OTHER